ExpressPoints
Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Gain key clinical insights fast, with this short slideset from CCO on key considerations for recognizing and managing ocular toxicities associated with antibody–drug conjugates.
Asim V. Farooq, MD
Joann Kang, MD
Paul G. Richardson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.55 MB
Released: November 29, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Related Content

Podcast with expert faculty discussing the latest evidence and associated clinical implications for BTK inhibitors in CLL and MCL presented at ASCO 2022, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: July 6, 2022

Commentary on management challenges and incorporating novel therapies for gynecologic cancers, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD Released: July 5, 2022

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings